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ABSTRACT
Extranodal non-Hodgkin’s lymphomas constitute 20-25% of overall non-Hodgkin’s lymphomas cases and can be managed with very dif-
ferent therapeutic strategies. Therefore, the Italian Society of Hematology and the two affiliate societies (the Italian Society of
Experimental Hematology and the Italian Group of Bone Marrow Transplantation) appointed a panel of experts to produce clinical prac-
tice-guidelines for the management of these conditions. Primary lung and mediastinal lymphomas were the objective of this part of the
project. The panel of experts produced the following key recommendations that were graded according to the strength of evidence and
clinical judgement. The first-line therapy for non-MALT primary lung non-Hodgkin’s lymphomas should include anthracycline-based
chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D). Rituximab association with chemotherapy needs
to be evaluated within approved clinical trials. Second-line therapy with high-dose chemotherapy and autologous stem cell transplan-
tation is recommended (grade B). In patients with MALT primary lung non-Hodgkin’s lymphomas, the recommended first-line therapy
should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B). Radiotherapy is to be reserved for patients
with a unique, small lesion in a poorly mobile site and with contraindication to surgery (grade D). Rituximab should be administered
only within approved clinical trials. For treatment of primary mediastinal large B-cell lymphomas, the recommended first-line therapy is
a chemotherapy and radiotherapy association (grade B). An anthracycline-based chemotherapy with CHOP, MACOP-B or VACOP-B is rec-
ommended (grade B). Rituximab combination with chemotherapy is highly suggested but only for patients enrolled into approved clin-
ical trials. Patients with an inadequate early response should be candidates for early intensification with high-dose chemotherapy (grade
C). Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treat-
ment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem cell transplantation (grade B).
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Introduction
In order to reserve patients for the best available
treatments and avoid the risk of inappropriate thera-
pies, since 2001 the Italian Society of Hematology (SIE)
has been supporting the development of clinical prac-
tice guidelines in the therapy of selected hematologic
malignancies. The Italian Society of Experimental
Hematology (SIES) and the Italian Group for Bone
Marrow Transplantation (GITMO) have since then
shared this aim. We present the first part of a project
aimed at producing recommendations for extranodal
non-Hodgkin’s lymphoma (NHL), dedicated to lung
and mediastinal primary NHL. The guidelines are
intended to support the clinical practice of hematolo-
gists, oncologists and internists who care for lym-
phoma patients.
Design and Methods
The methodology for developing SIE guidelines has
been extensively reported elsewhere.1 Eight senior
hematologists (the expert panel) and two literature
reviewers composed the working group. During the
first meeting, the areas of major concern in the manage-
ment of extranodal NHL were selected by generating
and rank-ordering clinical key-questions using the crite-
rion of clinical relevance, i.e. impact on the management
of patients and risk of inappropriateness, through a
Delphi process.2 The clinical domains and the key-ques-
tions that ranked highest formed the set of topics of the
present guidelines.
The evidence base was built through systematic
search of common medical literature databases for rel-
evant papers published up to March 2007. The search
was updated in January 2008. The proceedings of ASH
2003-2007, ASCO 2003-2007, and EHA 2003-2007
were scanned for relevant abstracts. Finally, the major
hematology, oncology and general medicine journals
(Blood, Journal of Clinical Oncology, British Journal of
Hematology, Bone Marrow Transplantation, Haematologica,
New England Journal of Medicine, Lancet) were manually
searched for relevant papers published from 1995. The
full reference list (including the abstracts of full papers)
is available on request from marchettim@smatteo.pv.it.
Full papers were assigned an evidence level, according
to the Scottish Intercollegiate Guideline Network.3
Based on the retrieved literature, the expert panel for-
mulated evidence-based recommendations. Judgment-
based recommendations were formulated by the use
of consensus methodologies when relevant areas could
not be addressed by the available evidence. A first
round of consensus for the proposed recommenda-
tions was obtained through paper questionnaires,
according to the Delphi technique.2 Nominal group
technique4 was used for the final recommendation
statements. The guidelines were reported according to
the COGS checklist by the Conference on Guideline
Standardization.5
Updating of the present guidelines is due in 2011.
Definitions
The present guidelines apply to patients with lung
and mediastinal primary lymphomas. The guidelines do
not apply to patients with acquired immunodeficiency
sustained by HIV or anti-graft immunosuppressive
agents (post-transplant lymphoproliferative disorders).
The expert panel agreed on the use of the Ann Arbor
staging system as modified by the Cotswolds meeting.6
Standard definitions for complete response (CR), com-
plete response untested (CRu), and partial remission
(PR) were adopted. An operational definition of elderly
patients was considered throughout the text that takes




Primary pulmonary lymphomas are clonal lymphoid
processes involving mainly the lung parenchyma and/or
large airways without extension to the extrapulmonary
sites at the diagnosis or during the three months after
the diagnosis. Hilar or mediastinal lymphnodes may be
enlarged but the neoplastic burden is more evident in
the lung tissue.8 The most common type of primary pul-
monary lymphoma is marginal zone B-cell lymphoma,
which arises from bronchus-associated lymphoid tissue,
and represents 70-90% of all primary pulmonary lym-
phomas.8 The translocation t(11;18)(q21;q21), which
results in a fusion of the cIAP2 region on chromosome
11q21 with the MALT1 gene on chromosome 18q21, is
documented in more than one-third of cases.9 Diffuse
large-B-cell lymphomas make up 10% of cases of pri-
mary pulmonary lymphomas,8 and the lung is the most
common site of involvement of lymphomatoid granulo-
matosis, an angiocentric and angiodestructive lympho-
proliferative disease.10-12
No paper comparing different procedures for initial
staging work-up in patients with lung lymphoma was
found. Therefore, the panel gave recommendations on
the use of specific investigations according to a good
clinical practice principle. In particular, the panel agreed
to include in staging primary lung lymphoma those tests
previously recommended for nodal diffuse large B-cell
lymphomas (DLBCL).1
The panel explicitly discussed the decision options for
first-line therapy for the NHL of the lung. Options were
restricted between the following therapeutic strategies:
watch and wait approach, surgery, chemotherapy and
chemotherapy followed by radiotherapy.
No comparative studies analyzed separately the watch
and wait option. One retrospective cohort analysis (evi-
dence level 3) reported 11 patients with MALT lym-
phoma of the lung who did not undergo treatment fol-
lowing initial diagnosis.13 The median time of observa-
tion without therapy was 28.1 months. Within this
time, all 11 patients showed at least stable disease. Six
of these 11 patients, however, had spontaneous regres-
sions and wax and wane phenomena of the pulmonary
lesions, but not of extrapulmonary manifestations. One
patient was referred for treatment after progression in
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the lung, while two patients experienced progression
outside the lung. This study suggests that MALT lym-
phoma of the lung is a very indolent disease with the
potential for spontaneous regression. The panel agreed
that patients diagnosed with pulmonary MALT lym-
phoma might not require immediate treatment in the
absence of symptoms and a watch and wait policy could
be adopted.
As direct evidence for initial treatment, the expert
panel considered 13 non-comparative, cohort studies,
dealing with small and heterogeneous series of patients
with lung lymphoma (level of evidence 3) (Table 1).14-25
Two outcome studies,26,27 and 3 phase II intervention
studies dealing with MALT lymphomas (level of evi-
dence 3)28-30 were also analyzed as translated evidence.
Early studies suggested that radical operation could be
considered the definitive therapeutic maneuver. Ferraro
et al. in 48 patients who underwent surgery for primary
pulmonary non-Hodgkin’s lymphoma [males 21 (44%);
females 27 (56%); mean age 61.8 yrs; asymptomatic
37.5%; MALT type 35 (73%); non-MALT type 13
(27%)] obtained a complete resection in 19 cases
(40%).20 In patients with MALT type lymphoma the
overall survival at one year was 91%, the overall sur-
vival at five years was 68% and the overall survival at
ten years was 53%. These data were weighted taking
into account the fact that this lymphoma is an indolent
disease usually with a long natural course, and that it is
a multifocal disease in which a radical resection is not
easy to perform. Furthermore, lung surgery is not with-
out risks since thoracic pain and lung function impair-
ment have been observed in about 10-15% of cases.
Radiotherapy alone with a total dose of 30-35 Gy in 15-
20 fractions (3-4 weeks) has been showed to guarantee
a low failure-free rate in MALT lymphomas.26 However,
in patients with primary pulmonary lymphomas of
MALT type the results were not as good as in the whole
population of MALT lymphomas; this may be explained
by the fact that lungs are mobile organs.26 Chemo-
therapy with anthracyclines or combined modality
therapy mainly with a CHOP regimen, was associated
with a 10-year lymphoma specific survival of 72% in a
study on 50 patients.21 In this study no differences in
survival were seen between subjects with low grade
MALT lymphoma and patients in which MALT lym-
phoma was associated to areas of large B-cell lym-
phoma. Zinzani et al.27 reported a series in which
patients received either fludarabine/mitoxantrone (FM)
or cyclophosphamide, vincristine and prednisone
(CVP). Twenty patients were treated with the FM regi-
men (25 mg/m2 per day fludarabine on days 1–3 and 10
mg/m2 mitoxantrone on day 1 only), 11 patients were
treated with the CVP regimen (400 mg/m2 per day
cyclophosphamide on days 1–5, mg/m2 vincristine on
day 1, and prednisone). In both regimens, courses were
administered at 3-week intervals for a total of 6 cycles.
The recurrence free survival rate was almost 100 % at
60 months. 
Regarding the role of rituximab in primary pulmonary
lymphoma of MALT type, so far there are only a few
case reports with conflicting results.31-33
Due to the absence of comparative studies, the panel
provided recommendations based mostly on consensus
formation techniques and according to a good clinical
practice principle (grade D). 
Recommendations
Patients with non-MALT primary lung NHL need pre-
treatment evaluation as for nodal diffuse large B-cell lym-
phomas (DLBCL) plus specific investigations including bron-
choscopy, thorax and abdomen CT scan with high-resolution
CT scan of the thorax, and pulmonary function tests including
transfer capacity for carbon monoxide (TLCO) (grade D).
Surgical resection is not required for debulking aims, but can
be requested for atelectasiae.
The recommended first-line therapy includes anthracycline-
based chemotherapy with CHOP or CHOP-like, MACOP-B
or MACOP-B-like regimens (grade B).
Rituximab association with chemotherapy needs to be eval-
uated within approved clinical trials.
Response should be evaluated as for nodal DLBCL, includ-
ing pulmonary function tests (grade D).
P. L. Zinzani et al. 
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Table 1. Case series including cases of primary pulmonary MALT lymphomas.
Number Lung Chemotherapy Rituximab Radiotherapy CR/PR 5 yr OS % 5 yr RFS %
of surgical (10 yr OS)
patients resection
Koss et al., 198314 44 NR NR NR NR NR 95 (85) NR
Kennedy et al., 198515 32 10 18 NR NR NR 90 (78) NR
Li et al., 199016 33 14 14 NR 5 NR 85 (75) <54
Cordier et al., 199517 64 42 18 NR 5 NR 94 (50) NR
Fiche et al., 199518 69 46 20 NR 6 NR 93.6% in low grades NR
Wislez et al., 199919 13 3 10 NR NR 7/5 100 NR
Ferraro et al., 200020 35 19 26 NR 2 NR 68 (53) NR
Kurtin et al., 200121 50 NR NR NR NR NR 85 (72) NR
Zinzani et al., 200322 12 4 10 NR NR 12/0 100 >50
Zucca et al., 200323 15 NR NR NR NR NR 100 75
Ahmed et al., 200424 22 6 10 10 2 9/10 <100 <60
Graham et al., 200525 17 6 8 1 NR NR 82% NR
NR: not reported.
Follow-up should be conducted as for nodal DLBCL, includ-
ing pulmonary function tests (grade D).
As for nodal DLBCL, second-line therapy with high-dose
chemotherapy and autologous SCT is recommended (grade B).
Patients with MALT primary lung NHL need pre-treatment
evaluation including bronchoscopy, thorax and abdomen CT
scan with high-resolution CT scan of the thorax, pulmonary
function tests including TLCO, bone marrow biopsy, immuno-
electrophoresis, LDH, β-2-microglobulin.
Patients with localized MALT primary lung NHL without
symptoms should be managed with a “watch and wait”
approach (grade D).
Surgery is not recommended for pre-treatment evaluation but
it can be performed in patients with localized disease, whenev-
er a wedge resection or middle lobe and lingula excision are
possible (grade D).
The recommended first-line therapy should include chloram-
bucil, CHOP, CHOP-like or fludarabine-containing regimens
(grade B).
Radiotherapy is to be reserved for patients with a unique,
small lesion in a poorly mobile site and with counterindication
to surgery (grade D).
Rituximab should be administered only within approved
clinical trials.
Post-treatment evaluation and follow-up of patients with
complete remission should follow the guidelines for nodal indo-
lent NHL, including also high-resolution CT of the thorax,
pulmonary function tests with TLCO (grade D).
Primary mediastinal large B-cell lymphomas
Primary mediastinal large B-cell lymphoma (PMLB-
CL) is a diffuse large B-cell lymphoma that arises in the
thymus and is considered a peripheral B-cell neoplasm.
Table 2 summarizes the clinical comparison of diffuse
large B-cell lymphoma and PMLBCL. In a review of
cases of non-Hodgkin’s lymphomas (NHL) from 9 cen-
ters all over the world, PMLBCL was found to account
for 2%.34 Molecular analysis and gene expression profil-
ing have identified PMBCL as a distinct and more favor-
able subgroup of DLBCL.35-37 Using array-based compar-
ative genomic hybridization, candidates genes were
selected in the context of NF-κB transcription activation,
human leukocyte antigen class I/II defects, impaired
apoptosis and Janus kinase/signal transducer and activa-
tor of transcription (JAK/STAT) activation.38 These data
confirm the genomic uniqueness of this tumor. PMLB-
CL appears to be a distinct clinicopathological entity,
characterized by locally invasive anterior mediastinal
mass with notable aggressiveness. The mass frequently
compromises the airway, determining a superior vena
cava syndrome.39 At the time of diagnosis, stage of dis-
ease is I-II in 80% of the patients. Mediastinal tumor is
larger than 10 cm (bulky mass) in 60-70% of patients,
infiltrating lung, chest wall, pleura, and pericardium.
Pleural or pericardial effusions are present in one-third
of cases. The invasive neoplasm results in cough, chest
pain, dyspnea, or complaints resulting from caval
obstruction. Spread to peripheral lymph nodes is infre-
quent, and marrow or cerebrospinal fluid involvement
unusual. Distant relapses tend to be extranodal, includ-
ing liver, gastrointestinal tract, kidneys, ovaries, adrenal
glands, pancreas, or central nervous system.40
Staging
No specific paper comparing different procedures in
patients with PMLBCL for initial staging work-up was
found. Outcome studies reporting Gallium67 scanning
(67GaSPECT) procedure for staging, response and relapse
assessment and follow-up were analyzed.41-43 18FDG-PET
was shown to be extremely useful for the assessment of
residual masses considering the elevated tracer uptake
that characterizes this lymphoma, but a longer experi-
ence is necessary. Thus, the panel produced recommen-
dations on the use of staging procedures according to a
good clinical practice principle.
Chemotherapy
Outcome or phase II non-comparative studies in
mediastinal lymphomas (evidence grade 3) reported the
results of approaches with first-generation44-53 to third-
generation34,40,42,54-60 chemotherapy protocols. One com-
parative study (evidence grade II) analyzing the use of
different chemotherapeutic regimens (CHOP or CHOP-
like vs. third-generation regimens) for advanced non-
Hodgkin’s lymphoma was used as indirect evidence.61
Early studies suggesting that PMLBCL were unusually
aggressive with a poorer prognosis with respect to other
large-cell lymphomas have been contradicted by more
recent reports. Complete response (CR) rates of 53-80%
have been reported after initial therapy with a 50-65%
overall survival rate at five years. The comparative
study showed that CHOP and intensive third-genera-
tion regimens produce equivalent results.61 Several
European centers have suggested that MACOP-B regi-
men may be superior to CHOP regimen.43,55-57,59
However, the panel claimed it was difficult to compare
the different types of protocols and to explain the rather
different CR and survival rates reported by different
institutions using similar regimens. Phase II studies
were judged to have been potentially influenced by
patient selection bias. Considering the published phase
II data by centers that have used both first-generation
chemotherapy regimens like CHOP and other more
aggressive third-generation ones like MACOP-B, the
results clearly favored the latter. Todeschini et al.57 used
CHOP in 6 patients with mediastinal lymphoma with-
out achieving a single CR. Lazzarino et al.55 treated 30
patients: the CR rate after CHOP was 36%, while that
after MACOP-B or VACOP-B was 73%. In a multicen-
ter study of 106 patients, the 3-year relapse-free survival
(RFS) was 38% in the 47 patients treated with CHOP
and 58% in the 62 patients treated with MACOP-B or
Guidelines for primary lung and mediastinal lymphomas
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Table 2. Comparison of DLBCL and PMLBCL.
DLBCL PMLBCL
Median age (years) 55 35
Nodal/extranodal presentation 65%/35% 0%/100%
Sex distribution (M:F) 1:1 1:4
Stage I-II/III-IV 40%/60% 80%/20%
Bulky disease 30% 60%-70%
VACOP-B.40 In 2 previous studies,43,59 Zinzani et al. used
MACOP-B regimen in 50 patients (a two-center
prospective trial) and in 89 patients (an Italian multicen-
ter prospective trial) respectively: the CR rates were
86% and 88% respectively, while the 5-year RFS rates
were 93% and 91% respectively. A retrospective
International Extranodal Lymphoma Study Group
(IELSG) study of 426 patients with PMLBCL confirmed
the superiority of the third-generation chemotherapy
strategies over first-generation ones in terms of sur-
vival.62 In addition, the same results have been reported
by Todeschini et al.63 in a retrospective study. 
The panel analyzed 3 outcome studies (evidence
grade 3) dealing with the use of high-dose approaches
including autologous stem cell transplantation and high-
dose sequential treatment. The data do not prove supe-
riority of high-dose chemotherapy over conventional
chemotherapy.64-66 The use of high-dose chemotherapy
supported by stem cell transplantation to consolidate
the initial response in high-risk patients resulted incon-
clusive.  
Radiation therapy 
The issue of adjuvant radiation therapy after
chemotherapy remains open. The excellent results
obtained in the GELA study34 without radiation therapy
have questioned its necessity. The panel considered 2
outcome analyses from two recent Italian studies,43,59
indicating that the addition of radiation therapy after
chemotherapy is of pivotal importance for the eradica-
tion of PMLBCL in terms of increasing the CR rate or
reinforcing existing CRs after induction chemotherapy.
In particular, 70% of the patients had residual mediasti-
nal tumor masses after chemotherapy (MACOP-B)
according to the first report,43 while it was 44% after
radiation therapy. Sixty-six percent of the patients
showed persistent abnormal uptake at 67Ga SPECT
after MACOP-B, while following radiation therapy,
19% of the patients were still 67Ga SPECT positive. In
the second study,59 after the chemotherapy regimen
(MACOP-B), 26% of the patients achieved a CR and
66% obtained a partial response (PR), giving an overall
response rate of 92%. After radiation therapy, 93% of
the patients who had already achieved a PR obtained
CR status. So, after the combined modality treatment,
88% of the patients achieved a CR.
Rituximab
Regarding the role of rituximab in PMLBCL treat-
ment, 4 observational and one phase II trials were ana-
lyzed by the panel.67-70 A statistically significant advan-
tage for the combination of rituximab plus DA-EPOCH
was observed in one study,67 and an increase in terms of
complete response, failure-free survival, and overall sur-
vival for the CHOP plus rituximab versus CHOP alone
was reported in another.68 In the latter study, the data
obtained with the combined treatment was equivalent
to the previously published MACOP-B/VACOP-B data
without rituximab. The preliminary data of an Italian
experience with MACOP-B plus rituximab achieved
comparable results when analyzing the historical
MACOP-B/VACOP-B alone data.69 Furthermore, in a
retrospective study Savage et al.70 showed that patients
treated with CHOP plus rituximab obtained the same
results in terms of 5-year overall survival as with
MACOP-B/VACOP-B patients. The panel considered
the evidence in favor of rituximab inclusive and further
randomized studies should consider the impact on these
comparisons. Recently, the International Extranodal
Lymphoma Study Group has started a trial comparing
first generation chemotherapy versus third generation
chemotherapy in association with rituximab.
Restaging
Several patients with PMLBCL have residual radi-
ographic abnormalities in the mediastinum even after
CR, so chest X-ray and CT scans do not provide a valid
basis for therapeutic decision making. 67Ga SPECT could
be the best tool for selecting those patients who really
require the addition of radiation therapy after
chemotherapeutic induction. In an observational (evi-
dence grade 3) study,43 60% of the patients with positive
67Ga SPECT and negative CT scan relapsed after com-
bined modality treatment, while no relapses were
observed with negative 67Ga SPECT and CT scan. This
restaging method allows identification of a subset of
patients with residual radiographic abnormalities who
need no further therapy (negative 67Ga SPECT) and of
poor prognosis patients who do require further treat-
ment. 
Recurrent disease 
Generally, patients with PMLBCL who obtain a CR
lasting longer than 18-24 months after diagnosis are
likely to be cured. In fact, most relapses occur within the
first 12 months after the completion of the front-line
treatment. A standard therapeutic option for patients
with relapsed disease has not yet been identified.
Considering the young age of these patients and the
pattern of relapse which spares the bone marrow, high-
dose chemotherapy supported by autologous stem cell
transplantation has been tested in 2 observational out-
come studies (grade of evidence 3) as rescue therapy.65,66
With this strategy, relapsed mediastinal lymphomas
seem to have a better prognosis with respect to the
other diffuse large cell lymphoma, with a 5-year dis-
ease-free survival of 55% and 35% respectively. In con-
trast, patients treated with a conventional second-line
chemotherapy or with radiation therapy on the medi-
astinum (for patients who did not undergo radiation
therapy after the front-line chemotherapy regimen)
have a median survival after relapse of a few months.
Recommendations
Staging work-up for primary mediastinal DLBCL should be
the same as for nodal DLBCL, but should also include chest
X-ray and PET scanning (grade D). As for nodal DLBCL, a
lumbar puncture with examination of cerebrovascular fluid is
recommended for those patients who have a high risk of CNS
involvement, such as those with an increased LDH level asso-
ciated with extranodal disease such as suprarenal, renal, liver
or ovary involvement (grade D).
The recommended first-line therapy is a chemotherapy and
radiotherapy association (grade B).
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An anthracycline-based chemotherapy with CHOP,
MACOP-B or VACOP-B is recommended (grade B).
Mediastinal RT should start within eight weeks from the last
dose of chemotherapy. A dose of at least 30 Gy should be
delivered to the original tumor volume (grade B).
Rituximab combination with chemotherapy is strongly sug-
gested but only for patients enrolled into approved clinical tri-
als (grade C).
Patients should receive an early evaluation with CT scan
during the first courses of chemotherapy (about half-way
through the programed courses) in order to identify patients with
inadequate response, i.e. less than partial response (grade D).
Patients with an inadequate early response should be candi-
dates for early intensification with high-dose chemotherapy
(grade C).
At the end of chemotherapy, patients should be evaluated
with CT scan and PET, in order to assess a progression which
occurred in the second half of the chemotherapy period (grade
D).
Patients should be ultimately evaluated at least 4-12 weeks
after the end of radiotherapy as for nodal DLBCL, i.e. includ-
ing CT scan and PET scan (grade D).
No definite recommendation can be currently formulated for
patients without a bulky disease who achieve a PET-negative
state at the end of chemotherapy: radiotherapy is less strongly
recommended in this clinical subset.
Patients who achieve a complete remission should be fol-
lowed every three months for two years, every six months for a
further three years and then annually for at least another five
years (grade D).
Patients with refractory or relapsed disease should undergo
rescue programs including intensive, non-cross-resistant
debulking treatment followed, in chemosensitive patients, by
high-dose chemotherapy and autologous SCT (grade B).
As for nodal DLBCL, patients with a high risk of failure
with high-dose chemotherapy and autologous SCT, such as
progressive disease or chemoresistant relapse, may benefit from
experimental approaches including allogeneic SCT (grade C).
Discussion
The existing scientific literature on the management
of pulmonary and mediastinal primary non-Hodgkin’s
lymphomas does not allow evidence-based recommen-
dations to be produced. A systematic literature revision
resulted in no comparative randomized intervention
studies dealing directly with lung or mediastinal lym-
phoma. As a consequence, consensus was a critical part
of the production of the present guidelines. Experts in
the field judged the existing evidence and formulated
recommendations in a decision process grounded on the
concept that the relative benefit-to-risk balance of the
decisions should result from a partially subjective
process. The theoretical value of the experts’ consensus
approach to influencing practice is the assumption that
such knowledgeable experts have an implicit and com-
prehensive mastery of the scientific and practical infor-
mation that would yield the most appropriate recom-
mendations.
In a preliminary prioritization process, the expert
panel listed the most relevant clinical key-questions in
the therapeutical pathway of extranodal lymphomas.
This was aimed at supporting a rational use of novel
technologies still under evaluation, such as PET in the
staging process of the lung and mediastinal lymphoma,
third generation chemotherapies, and the new thera-
peutic approaches that are under experimentation, such
as rituximab. The resulting recommendations may not
receive a comparative evaluation with others resulting
from a similar structured group discussion process. In
fact, due to the rarity of the pathological condition and
the absence of a high grade of scientific evidence, no
other published guidelines on extranodal lymphomas
were found.
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